Drug intelligence / Profile preview

Chaige Qingsan Decoction

Development stage: Preclinical
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Chaige Qingsan Decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is specifically designed to treat influenza A in patients presenting with the 'external cold and internal heat' syndrome. The decoction aims to alleviate symptoms by clearing interior heat and resolving exterior cold. It has been evaluated in prospective cohort studies in China to compare its clinical efficacy and safety against the standard antiviral medication oseltamivir in patients aged 14 to 80 years.

Other names: Chaige Qingsan

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HSD11B2 (11β-HSD2)HMGB1 (High mobility group protein B1)GR (Glucocorticoid receptor)ESR2 (ERβ)

Beyond the preview

Go deeper on Chaige Qingsan Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chaige Qingsan Decoction.

Explore the full profile